Basic Information
Adrovance
Regulatory Information
EMEA/H/C/000759
Authorised
January 4, 2007
October 18, 2006
28
December 5, 2024
Company Information
Netherlands
Kloosterstraat 6 5349 AB, Oss
Organon NV
Active Substances Detail
colecalciferolalendronic acid (as sodium trihydrate)
alendronic acid (as sodium trihydrate)
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency. Adrovance reduces the risk of vertebral and hip fractures.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Adrovance. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adrovance.